Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Statement

23 Apr 2009 08:55

RNS Number : 0351R
ViaLogy PLC
23 April 2009
 



ViaLogy 

VIALOGY ACHIEVES ANOTHER OIL WELL SUCCESS 

LondonApril, 23, 2009. Vialogy (LSE: VIY) announces another successful well in the Galba Prospect in South Central Texas. This well success reinforces operational and commercial validation of the company's QuantumRD™ software-based seismic interpretation service for oil and gas reservoir discovery and characterization. ViaLogy accurately predicted the size, location and formation porosity for this prospect. 

The new producing well, called Mary Ridgeway #1, is located on the Galba lease owned by ViaLogy's partner Atascosa Exploration LLC of San Antonio. The Mary Ridgeway#1 well is estimated to hold larger recoverable reserves compared to ViaLogy's previously announced Cindy Bartlett#2 well discovery announced in March 2009. As before, Vialogy predicted the subsurface hydrocarbon reservoir boundaries, the porosity of the oil-bearing Bartosh sands, formation depth, and positioned the well. Prospect estimates were confirmed by the well-logging and independent subsequent core laboratory analysis. The companies will be releasing actual figures over the next few days, including dollar estimates of recoverable reserves. As announced earlier, under its current contract with Atascosa, Vialogy will receive 5% Back-In-After-Payout working interest in the well. 

As in the previous successful oil find in March, Vialogy's proprietary QuantumRD served as the analytical tool for assessing 3D seismic data sets. The technology exploits subtle variations in seismic noise to overcome limitations in current processing and interpretation techniques, making possible a more accurate analysis of seismic data now in widespread use in the industry. 

Vialogy now turns its attention to its next contracted Atascosa well project, with drilling expected to begin before the end of Q2 2009, and, equally as important, to business opportunities with new customers. Interest in the technology appears considerable. 

Vialogy CEO, Robert W. Dean, said, "This successful well marks a major step forward for the company in demonstrating the capability of QuantumRD and its relevance in the oil patch. Our hope and intention is to enable multiple producing wells in the coming months, cautioning at the same time that no seismic interpretation technique can be one hundred percent effective one hundred percent of the time. What we can bring to the industry over time is a major improvement in the ratio of drilling dry holes to producing wells, and thus considerable cost savings." 

For further information please contact: 

ViaLogy  Robert W Dean, President & CEO - US +1 626-296-6337 (mobile: +1 703-589-3807)  Terry Bond, Chairman - UK & Europe +44 (0) 1235-834734 (mobile: 07860 842756) 

Atascosa Exploration LLC  John D. Mullins, CEO (+1 210-402-3656)  Nominated Advisor (Seymour Pierce)  Mark Percy +44 (0) 20-7107-8000 

Brokers to ViaLogy PLC  St. Helen's Capital +44 (0) 7628 5582 

About ViaLogy: Network Centric Signal Processing  ViaLogy is a leading innovator of network-centric, real-time signal processing platforms for sensor applications. ViaLogy is currently deploying and designing computational systems, powered by its patented technologies, for applications in life sciences, public safety and security, surveillance, defense and geosiesmology. ViaLogy focuses on market driven problems where automation, timeliness, quality and reliability of information processing are essential. ViaLogy's core competency incorporates rapidly and accurately detecting weak signals buried in high noise background and clutter. This technology can be employed to solve problems involving sensor integration and information overload challenges involving video, telephony and control sensors, as well as for enhancement of numerous signal processing applications. For more information, visit our website at www.ViaLogy.com

Except for statements of historical fact, the information presented herein constitutes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied. 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTPUUUACUPBUMW
Date   Source Headline
14th Dec 20217:00 amRNSHalf-year Report
6th Dec 20217:00 amRNSNotice of Half-year results
18th Nov 20217:00 amRNSDPYD screening recommended in Spain
28th Oct 20217:00 amRNSRanger® Technology to be presented at Labroots
26th Oct 20217:00 amRNSHalf-year Trading update
29th Sep 20217:00 amRNSResult of AGM
28th Sep 20213:00 pmRNSAGM update
28th Sep 20217:00 amRNSAGM Statement
15th Sep 20217:00 amRNSShare option awards
1st Sep 20217:00 amRNSISO 15189:2012 accreditation received
1st Sep 20217:00 amRNSNotice of AGM and Annual Report 2021
19th Aug 202112:04 pmRNSCOVID-19 Surge testing contract
11th Aug 20217:01 amRNSEarn-out Milestone, Issue of Equity & TVR
11th Aug 20217:00 amRNSAudited Final results&unaudited Q1 business update
6th Aug 20217:00 amRNSConfirmation of Results Date
23rd Jul 20217:00 amRNSNotice of Results
1st Jul 202111:09 amRNSHolding(s) in Company
21st Jun 20217:00 amRNSSecond Strategic Partner for Coastal Genomics
18th Jun 20217:00 amRNSContract Award: DPYD testing kits for NHS Wales
17th Jun 20214:32 pmRNSExercise of Options
9th Jun 20217:00 amRNSMulti-year licence and supply agreement
21st May 20214:30 pmRNSDirector/PDMR Shareholding
19th May 20217:00 amRNSDistribution Partnership
18th May 20217:00 amRNSLaunch of IONA Care NIPT service offering
17th May 20217:00 amRNSFurther testing service agreement for MHC
29th Apr 20217:00 amRNSFull year Trading update
26th Apr 20217:00 amRNSFurther National Microbiology Framework awards
19th Apr 20211:21 pmRNSFurther National Microbiology Framework contract
19th Apr 20217:00 amRNSNational Framework contract award
12th Apr 20217:00 amRNSEarn-out Milestone, Issue of Equity & TVR
6th Apr 20212:43 pmRNSTesting service agreement with MyHealthCheckedplc
6th Apr 20211:54 pmRNSAgreement with Boots for COVID-19 sample kits
29th Mar 20214:00 pmRNSCOVID-19 update
23rd Mar 20217:00 amRNSShare option exercises and awards
19th Mar 20217:00 amRNSTwin Pregnancy study published using IONA® Test
17th Mar 20217:00 amRNSAppointment of VP of Sales North America
11th Mar 20217:00 amRNSYourgene Genomic Services portfolio expansion
1st Mar 20217:00 amRNSFirst US Supply Agreement
22nd Feb 20217:00 amRNSPartnership with NPH
10th Feb 202110:51 amRNSCorrection: Director / PDMR Shareholding
10th Feb 20217:00 amRNSDirector/PDMR Shareholding
8th Feb 20217:00 amRNSTrading update
13th Jan 20217:00 amRNSDPYD screening recommended in Belgium
11th Jan 20217:00 amRNSClarigene® SARS-CoV-2 Product Update
8th Jan 20217:00 amRNSIssue of Share Options
24th Dec 20207:00 amRNSCOVID-19 update
17th Dec 20207:00 amRNSHalf-year Report
15th Dec 20207:00 amRNSNotice of Half-year Results
2nd Dec 20207:00 amRNSDPYD kits recommended by NHS England
2nd Dec 20207:00 amRNSGenomic testing service launch and Change of name

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.